International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis

Abstract

The outcomes observed in this cohort seem comparable to those in the non-dialysis population. Thus, to the best of our knowledge, this is the largest and most informative dataset regarding systemic treatment outcomes in HCC patients undergoing dialysis.